- Tumor Vaccine
- Adjuvant Molecules
- Liposome Molecules
- Adjuvant System
Introduction to Tumor Vaccine Products
AYK103 | AYK103 is a tumor in situ vaccine composed of a novel adjuvant. The new immune adjuvant used in AYK103 can reshape the tumor immune microenvironment, activate APC cells in tumor tissue, and promote the infiltration of a large number of CD8+T cells into the tumor. Simultaneously generating a large number of memory T cells to respond to the attack of re inoculating tumor cells. It has good anti-tumor effects on multiple tumor models such as melanoma, colorectal cancer, liver cancer, and lung cancer. |
AYK200 | AYK200 is a prokaryotic expression recombinant protein vaccine built on the company's technology platform. Currently, multiple technical difficulties have been solved and the preparation of the recombinant protein has been completed. We are conducting preclinical research. |
AYK202 | AYK202 is a small molecule drug independently developed by Anyikon, which can effectively inhibit the growth of various solid tumors. It has completed concept validation and is planned to be submitted to IND by 2025. |
AYK203 | AYK203 is a novel therapeutic tumor vaccine that utilizes heterologous T cells to attack tumors. Previous animal trials have confirmed its good anti-tumor effects, and concept validation has been completed. The IND is planned to be submitted in 2026. |
留言咨询
Name*
*Phone*
*Email
Details